Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Carey, John B ^a   Vrdoljak, Anto ^a   O'Mahony, Conor ^b   Hill, Adrian V S ^c   Draper, Simon J ^c   Moore, Anne C ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTACOID; CYTOKINE; MALARIA VACCINE; PROTOZOON ANTIBODY; VIRUS ANTIBODY;

ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; FEMALE; GENE VECTOR; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; LYMPH NODE; MALARIA; METABOLISM; MOUSE; PLASMODIUM YOELII; PROCEDURES;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; ANTIGENS; CYTOKINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION; INFLAMMATION MEDIATORS; INJECTIONS, INTRADERMAL; LYMPH NODES; MALARIA; MALARIA VACCINES; MICE; PLASMODIUM YOELII;

EID: 84906675665     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06154     Document Type: Article

References (42)

1. Hill, A. V. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 366, 2806-2814 (2011).
2. Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8, 62-73 (2010).
3. de Cassan, S. C.&Draper, S. J. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 12, 365-378 (2013).
4. Draper, S. J. et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5, 95-105 (2009).
5. Ewer, K. J. et al. Protective CD8(1) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature communications 4, 2836 (2013).
6. Sheehy, S. H. et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20, 2355-2368 (2012).
7. Sheehy, S. H. et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7, e31208 (2012).
8. Sumida, S. M. et al. Neutralizing antibodies and CD81 T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78, 2666-2673 (2004).
9. Reyes-Sandoval, A. et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38, 732-741 (2008).
10. Barnes, E. et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4, 115ra111 (2012).
11. Scallan, C. D., Tingley, D. W., Lindbloom, J. D., Toomey, J. S. & Tucker, S. N. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 20, 85-94 (2013).
12. Croyle, M. A. et al. Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3, e3548 (2008).
13. Xiang, Z. Q. et al.Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77, 10780-10789 (2003).
14. Appledorn, D.M., Aldhamen, Y. A., Godbehere, S., Seregin, S. S. & Amalfitano, A. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity. Clin Vaccine Immunol 18, 150-160 (2011).
15. Carey, J. B. et al. Microneedle Array Design Determines the Induction of Protective Memory CD81 T cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS One 6, e22442 (2011).
16. van der Maaden, K., Jiskoot, W. & Bouwstra, J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 161, 645-655 (2012).
17. Gandhi, G. et al. Projections of costs, financing, and additional resource requirements for low-and lower middle-income country immunization programs over the decade, 2011-2020. Vaccine 31 Suppl 2, B137-148 (2013).
18. de Cassan, S. C. et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187, 2602-2616 (2011).
19. Lindsay, R. W. et al. CD81 T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c1 dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 185, 1513-1521 (2010).
20. Hensley, S. E. et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 15, 393-403 (2007).
21. Pine, S. O. et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 6, e18526 (2011).
22. Ophorst, O. J. et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25, 6501-6510 (2007).
23. Forbes, E. K. et al. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein. PLoS One 7, e44943 (2012).
24. Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14, 819-821 (2008).
25. Meyer, J. et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine 31, 1026-1033 (2013).
26. O'Hara, G. A. et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205, 772-781 (2012).
27. Douglas, A. D. et al. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167-7178 (2010).
28. Goodman, A. L. et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 78, 4601-4612 (2010).
29. Dicks, M. D. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7, e40385 (2012).
30. Hirunpetcharat, C. et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD41 T cells. J Immunol 159, 3400-3411 (1997).
31. Enfield, J. et al. In vivo dynamic characterization of microneedle skin penetration using optical coherence tomography (OCT). J. Biomedical Optics 15, 046001 (2010).
32. Haq, M. I. et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices 11, 35-47 (2008).
33. Paleco, R., Vucen, S. R., Crean, A.M., Moore, A.&Scalia, S. Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles. Int J Pharm 472, 206-213 (2014).
34. Vucen, S. R. et al. Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles. J Pharm Pharmacol 65, 1451-1462 (2013).
35. Biswas, S. et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 6, e20977 (2011).
36. Sheehy, S. H. et al. Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Mol Ther (2011).
37. Peters, W. et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 31, 1752-1758 (2013).
38. Bachy, V. et al. Langerin negative dendritic cells promote potent CD81 T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci USA 110, 3041-3046 (2013).
39. Vrdoljak, A. et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 159, 34-42 (2012).
40. DeMuth, P. C. et al. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol 31, 1082-1085 (2013).
41. Wilke, N., Mulcahy, A., Ye, S. R. & Morrissey, A. Process optimization and characterization of silicon microneedles fabricated by wet etch technology. Microelectronics Journal 36, 650-656 (2005).
42. Ahlborg, N., Ling, I. T., Howard, W., Holder, A. A. & Riley, E. M. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region. Infect Immun 70, 820-825 (2002).